| Revenue growth | H2FY26 revenue up 23.1% YoY to ₹41.6 Cr. |
|---|---|
| Margins | EBITDA margin surged 2625 bps HoH to 26.32% in H2. |
| Demand visibility | Strong sales momentum returned in H2 with restored customer demand. |
| Management confidence | High; cited decisive rebound after intentional H1 credit tightening. |
Growth
H2FY26 revenue grew 23.1% YoY and 64.4% HoH. FY26 annual revenue reached ₹66.9 Cr, up 8.6% YoY.
Outlook
Targeting 500 standardized Xelix clinics by expanding into skin and body aesthetics verticals from a hair-first focus.
Risks
Historically high inventory and credit-driven sales softened H1 performance; regulatory shifts during private-to-public conversion.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹66.00
- Market cap
- ₹93.54 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 14.1×Sector 53.1×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Business Update
Aakaar Medical Technologies provided an operational update for Q1 FY2026-27, detailing expansion in its clinic network, distributor count, and overall sales force effectiveness.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies addressed an NSE notice regarding Regulation 44(3) non-compliance, stating the lapse was inadvertent and that corrective measures have been implemented.
Aakaar Medical Technologies Legal & Regulatory
Aakaar Medical Technologies submitted a share‑capital audit reconciliation reporting issued capital of ₹14.17 Crore. The filing satisfies SEBI (Depositories and Participants) Regulation 76 requirements.
- Value
- ₹14.17 Cr
Aakaar Medical Technologies Management Change
Aakaar Medical Technologies appointed NAM & ASSOCIATES as Secretarial Auditor for a five-year term. The firm brings extensive experience in corporate and foreign exchange laws.
- Execution
- 60 months
Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies held its 13th AGM on June 30, 2026. Key outcomes include financial approval and increasing authorized share capital.
Aakaar Medical Technologies Earnings Call: Key Takeaways
Aakaar Medical Technologies reported FY26 revenue of INR 67 Cr (up 8.6%) and PAT of INR 6.63 Cr (up 10%). The company is shifting towards an asset-light DODO clinic model via its Xelix platform.